NO20052987L - Forbindelser for normalisering av sovn/vaken-syklusen. - Google Patents

Forbindelser for normalisering av sovn/vaken-syklusen.

Info

Publication number
NO20052987L
NO20052987L NO20052987A NO20052987A NO20052987L NO 20052987 L NO20052987 L NO 20052987L NO 20052987 A NO20052987 A NO 20052987A NO 20052987 A NO20052987 A NO 20052987A NO 20052987 L NO20052987 L NO 20052987L
Authority
NO
Norway
Prior art keywords
sleep
compound
methods
normalizing
containing compound
Prior art date
Application number
NO20052987A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052987D0 (no
Inventor
Scott Lukas
Perry F Renshaw
Original Assignee
Mclean Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mclean Hospital Corp filed Critical Mclean Hospital Corp
Publication of NO20052987D0 publication Critical patent/NO20052987D0/no
Publication of NO20052987L publication Critical patent/NO20052987L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20052987A 2002-12-20 2005-06-17 Forbindelser for normalisering av sovn/vaken-syklusen. NO20052987L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43545702P 2002-12-20 2002-12-20
PCT/US2003/040450 WO2004058160A2 (fr) 2002-12-20 2003-12-17 Composes pour la normalisation du cycle sommeil/etat de veille

Publications (2)

Publication Number Publication Date
NO20052987D0 NO20052987D0 (no) 2005-06-17
NO20052987L true NO20052987L (no) 2005-08-29

Family

ID=32682243

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052987A NO20052987L (no) 2002-12-20 2005-06-17 Forbindelser for normalisering av sovn/vaken-syklusen.

Country Status (12)

Country Link
US (1) US20040176316A1 (fr)
EP (1) EP1589979A4 (fr)
JP (2) JP4717444B2 (fr)
CN (1) CN100563660C (fr)
AU (1) AU2003299715A1 (fr)
BR (1) BR0317586A (fr)
CA (1) CA2508995A1 (fr)
MX (1) MXPA05006781A (fr)
NO (1) NO20052987L (fr)
RU (1) RU2366428C2 (fr)
UA (1) UA88869C2 (fr)
WO (1) WO2004058160A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030294B2 (en) * 2000-03-16 2011-10-04 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
ES2427347T3 (es) * 2002-11-08 2013-10-30 The Mclean Hospital Corporation Compuestos para el tratamiento de la dependencia y la abstinencia de tabaco
WO2005034874A2 (fr) * 2003-10-08 2005-04-21 The Mclean Hospital Corporation Efficacite amelioree d'une therapie aux acides gras omega-3 dans le traitement de troubles psychiatriques et d'autres indications
EP1727554A4 (fr) * 2003-10-08 2009-09-30 Mclean Hospital Corp Methodes de traitement de troubles psychiatriques, de troubles lies a l'abus d'alcool et de drogues ainsi que d'autres troubles au moyen de combinaisons contenant des acides gras omega 3
US20090215714A1 (en) * 2004-06-10 2009-08-27 Perry Renshaw Pyrimidines, such as cytidine, in treatments for patients with biopolar disorder
US7737128B2 (en) * 2004-06-10 2010-06-15 The Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
WO2006020703A1 (fr) * 2004-08-11 2006-02-23 The Mclean Hospital Corporation Compose pour le traitement de la dependance, de la suppression et de l'usage de la marijuana
HUE031206T2 (en) * 2005-05-23 2017-06-28 Massachusetts Inst Technology Formulations and methods of application containing PUFA
TW200827367A (en) * 2006-10-26 2008-07-01 Kyowa Hakko Kogyo Kk A therapeutic agent for irritable bowel syndrome
CA2704481C (fr) * 2007-11-16 2015-12-22 Bio Clinical Development, Inc. Composition energetique comestible a faible teneur en cafeine, comprenant de la choline
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
JP5426918B2 (ja) * 2009-04-20 2014-02-26 株式会社 伊藤園 ウリジンを含有する抗疲労剤又は体力向上剤
JP2011032232A (ja) * 2009-08-04 2011-02-17 Ito En Ltd 興奮抑制用又は鎮静用組成物及びこれを含む飲食品
JP5989319B2 (ja) 2011-10-06 2016-09-07 ライオン株式会社 睡眠の質改善剤
EP2854856B1 (fr) * 2012-06-04 2019-01-23 Pfizer Inc Utilisation d'agonistes ou d'antagonistes des récepteurs de la ghréline pour traiter les troubles du sommeil
WO2014163150A1 (fr) * 2013-04-05 2014-10-09 ライオン株式会社 Composition à usage interne
EP3056096B1 (fr) * 2015-02-05 2019-07-24 Smart Sleep GmbH Utilisation d'un complément alimentaire contenant de la créatine pour réduire le besoin naturel de sommeil ou pour adapter plus rapidement le rythme circadien à de nouveaux fuseaux horaires
EP3391886A1 (fr) 2017-04-19 2018-10-24 Novartis AG Utilisation d'un agoniste inverse h3r pour le traitement de trouble du travail par équipes

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4048316A (en) * 1974-03-04 1977-09-13 Penn Nathar W Composition for antagonizing the narcotic effects of barbiturate addiction and withdrawal effects, and for treatment of barbiturate poisoning
US4115576A (en) * 1974-04-02 1978-09-19 Penn Nathar W Compositions and method of employing the same for inhibiting alcohol intoxication
US4027017A (en) * 1974-07-16 1977-05-31 Chugai Seiyaku Kabushiki Kaisha Method of treating alcoholism
IT1200589B (it) * 1985-02-14 1989-01-27 Gibipharma Spa Derivati naturali attivita farmagologica
JPS63208524A (ja) * 1987-02-25 1988-08-30 Nippon Oil & Fats Co Ltd 睡眠リズム改善剤
US7173017B1 (en) * 1987-10-28 2007-02-06 Wellstat Therapeutics Corporation Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
JPH0418034A (ja) * 1990-05-11 1992-01-22 Kanegafuchi Chem Ind Co Ltd 点眼組成物
US5635486A (en) * 1990-05-11 1997-06-03 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Ophthalmic composition comprising a sleep adjusting substance
JP3153551B2 (ja) * 1991-05-29 2001-04-09 アボツト・ラボラトリーズ 認識機能を高めるイソオキサゾールおよびイソチアゾール化合物
US5704361A (en) * 1991-11-08 1998-01-06 Mayo Foundation For Medical Education And Research Volumetric image ultrasound transducer underfluid catheter system
GB9200293D0 (en) * 1992-01-08 1992-02-26 Wyeth John & Brother Ltd Piperazine derivatives
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
US5472958A (en) * 1994-08-29 1995-12-05 Abbott Laboratories 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function
CN1488353A (zh) * 1995-03-06 2004-04-14 Ӣ��Ŧ¡��ҩ���޹�˾ 用于治疗发生缺血患者的组合物
US5888532A (en) * 1996-08-16 1999-03-30 Pritsos; Chris A. Treatment of alcoholism and related disorders with (nicotinamide-adenine dinucleotide) phosphate derivatives
GB9623859D0 (en) * 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
US5958896A (en) * 1997-08-08 1999-09-28 The Mclean Hospital Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
DE69937198T2 (de) * 1998-07-31 2008-07-03 Massachusetts Institute Of Technology, Cambridge Behandlung der alzheimer-krankheit durch erhöhung des cytidin-spiegels in vivo
DE19929995B4 (de) * 1999-06-30 2004-06-03 Skw Trostberg Ag Verwendung von Kreatin und/oder Kreatin-Derivaten zur Behandlung von Befindlichkeitsstörungen bei Frauen
US8030294B2 (en) * 2000-03-16 2011-10-04 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
ES2170649B1 (es) * 2000-03-29 2003-06-16 Ferrer Int Uso de la cdp-colina en el tratamiento de la abstinencia alcoholica.
US6277855B1 (en) * 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US20030114415A1 (en) * 2001-12-14 2003-06-19 Wurtman Richard J. Compositions and methods for treating and preventing memory impairment using citicoline

Also Published As

Publication number Publication date
CA2508995A1 (fr) 2004-07-15
JP4717444B2 (ja) 2011-07-06
CN100563660C (zh) 2009-12-02
MXPA05006781A (es) 2005-09-30
EP1589979A2 (fr) 2005-11-02
RU2005122934A (ru) 2006-01-20
NO20052987D0 (no) 2005-06-17
AU2003299715A8 (en) 2004-07-22
WO2004058160A2 (fr) 2004-07-15
BR0317586A (pt) 2005-11-22
CN1750833A (zh) 2006-03-22
JP2006513214A (ja) 2006-04-20
WO2004058160A3 (fr) 2005-03-31
US20040176316A1 (en) 2004-09-09
EP1589979A4 (fr) 2009-04-01
AU2003299715A1 (en) 2004-07-22
UA88869C2 (ru) 2009-12-10
RU2366428C2 (ru) 2009-09-10
JP2011102319A (ja) 2011-05-26

Similar Documents

Publication Publication Date Title
NO20052987L (no) Forbindelser for normalisering av sovn/vaken-syklusen.
DE60215919D1 (de) 4-fluoro-n-indan-2-yl benzamid und seine verwendung als arzneimittel
EA200400881A1 (ru) Азаарилпиперазины
ATE329590T1 (de) Verwendung von fumarsäurederivaten zur behandlung mitochondrialer krankheiten
DK0690851T3 (da) Guanidin-derivater, som er anvendelige til behandling
AU7076094A (en) Use of modafinil for the treatment of sleep apnoea and ventilation problems of central origin
EP1834961A3 (fr) Conception d'analogues de chimiokines permettant de traiter des maladies humaines
NO20083036L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon
EA201100245A1 (ru) Новый холиновый сокристалл эпалрестата
PT1261333E (pt) Utilizacao de topiramato para o tratamento e diagnostico de transtorno do sono relacionado com a respiracao e meios para realizar o metodo e o diagnostico
ATE421313T1 (de) Verwendung einer dihydrochalcon-reichen phenolischen fraktion für eine kosmetische behandlung
ATE289816T1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
DK1572699T3 (da) Krystallinske cefdinirsalte
ATE429916T1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
EE200200337A (et) Uued ühendid ning nende kasutamine
NO20065079L (no) Materialer og metoder for behandling av koaguleringssykdommer
NO20071704L (no) Prostaglandinderivater for behandling av gastrointestinal forstyrrelse
ATE218535T1 (de) Aminotetralinderivate, deren zusammensetzungen sowie deren verwendung
PL319868A1 (en) Novel method of treating diseases
EA200200518A1 (ru) Способ и композиция для лечения заболеваний легких
CY1107756T1 (el) Αναλογα θειου της 21-υδροξυ-6, 19-οξειδοπρογεστερονης (21oh-6οp) για τη θεραπεια πλεονασματος γλυκοκορτικοειδων
ATE458495T1 (de) Therapeutische zubereitung für autoimmune erkrankungen
EA200600989A1 (ru) Применение габоксадола для лечения бессонницы
NO20024381L (no) Preparat for anvendelse ved behandling av okular hypertensjon og gluakom
DK1399142T3 (da) Anvendelse af acetyl-L-carnitin i kombination med biotin til behandlingen af patienter med type-2 insulinresistent diabetes mellitus

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application